AA
SUPN icon

AQR Arbitrage’s Supernus Pharmaceuticals SUPN Stock Holding History

AQR Arbitrage’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-43,444
Closed -$1.52M – 537
2019
Q1 		$1.52M Buy
+43,444
New +$1.62M 0.02% 244

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

AQR Arbitrage's SUPN Position: Q2 2019 in Review

AQR Arbitrage sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 43,444 shares — an estimated $1.52M sold.

AQR Arbitrage first reported a position in SUPN in Q1 2019 and held it in 1 quarter. The position peaked at $1.52M in Q1 2019. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

  • AQR Arbitrage reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • AQR Arbitrage sold 43,444 Supernus Pharmaceuticals shares in Q2 2019, an estimated $1.52M.
  • AQR Arbitrage first reported a position in Supernus Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • AQR Arbitrage's Supernus Pharmaceuticals position peaked at $1.52M in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on AQR Arbitrage's 13F filing for Q2 2019, filed 14 Aug 2019.